Detection of B. fragilis group and diversity of bft enterotoxin and antibiotic resistance markers cepA , cfiA and nim among intestinal Bacteroides fragilis strains in patients with inflammatory bowel disease
| Autor: | Hamid Asadzadeh Aghdaei, Mehdi Ghobakhlou, Marjan Rashidan, Mohammad Reza Zali, Masoumeh Azimirad, Masoud Alebouyeh |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male 0301 basic medicine Imipenem Bacterial Toxins 030106 microbiology Microbial Sensitivity Tests Drug resistance Polymerase Chain Reaction Microbiology beta-Lactamases Agar dilution Bacteroides fragilis Young Adult 03 medical and health sciences Minimum inhibitory concentration Antibiotic resistance Bacterial Proteins Ampicillin Drug Resistance Bacterial medicine Humans Aged biology business.industry Metalloendopeptidases Sequence Analysis DNA Middle Aged Bacteroides Infections Inflammatory Bowel Diseases biology.organism_classification Bacterial Load Anti-Bacterial Agents Metronidazole Infectious Diseases Female business medicine.drug |
| Zdroj: | Anaerobe. 50:93-100 |
| ISSN: | 1075-9964 |
| DOI: | 10.1016/j.anaerobe.2018.02.005 |
| Popis: | We compared frequency of the members of B. fragilis group in 100 and 20 colon biopsy specimens of inflammatory bowel disease (IBD) and non-IBD patients. Agar dilution and PCR were orderly used to detect minimal inhibitory concentration of ampicillin, imipenem, and metronidazole, and carriage of related resistance genes cepA, cfi, and nim. B. fragilis group was detected in 38% of IBD (UC: 36/89; CD:1/11) and 25% (5/20) of non-IBD patients. While B. vulgatus (UC: 20/36, CD: 1/2, control: 1/6); B. fragilis (UC: 18/36, CD: 1/2, control: 5/6); B. ovatus (UC: 2/36); B. caccae (UC: 1/36); and B. eggerthii (UC: 1/36) were characterized, colonization of B. thetaiotamicron, B. merdae, B. distasonis, B. stercoris and B. dorei species was not detected in these specimens. Co-existence of B. fragilis + B. vulgatus (5 patients) and B. vulgatus + B. caccae (1 patient) was detected just in UC patients. bft was detected among 31.5% (6/19) of B. fragilis strains in the IBD and 40% (2/5) in the non-IBD groups. Nearly, 73.6% of the strains from the patient group and 80% in control group harbored cepA; 31.5% and 20% in the patients and control groups harbored cfiA, and none of them harbored nim determinant. Co-occurrence of the cepA and cfiA was orderly detected in 10.5% (2/19) and 20% (1/5) of the strains in these groups. The resistance rates were detected as 95.8% (23/24 (to ampicillin (MIC range of ≤0.5-≥16 μg/ml), 0% to metronidazole and 29.1% to imipenem (7/24, MIC range ≤4–32 μg/ml). Nearly 25% (6/24) of the strains were resistant to ampicillin and imipenem, simultaneously. No statistically significant difference was detected between the IBD and control groups for drug resistance phenotypes. Statistical analysis showed significant associations between resistance to ampicillin or imipenem and carriage of cepA or cfiA, respectively (p value = 0.0007). PCR results on the extracted plasmids confirmed their roles in carriage of cfiA and cepA. These data provide guide for antibiotic therapy and highlights wide distribution of β-lactam resistant B. fragilis strains in patients with IBD and non-IBD intestinal disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect